OakChart

Tevogen Inc

TVGNHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

6.00+0.28 (4.90%)
2026-11-12 06:16 CET
Market cap
39.07 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-22.14 USD m
Free cash flow, TTM
-11.63 USD m
EPS diluted, TTM
-5.83
P/E
-
Compare

Price

TVGN against its 20, 50 and 200-day averages
2050200
5.0010.0015.0020.0025.0089K178KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TVGNclose 6.0020-day 6.2150-day 6.78200-day 7.796.0052w high52w low

76.1% under the 52-week high of 25.12 on 10 Nov 2025. 52-week low 3.64 on 20 Jul 2026. Last 15 sessions, 42.7% high to low

Volume 0.38× normal · the line is the 50-bar volume average

Profile

TVGN
52-week range, 11% of the way up
3.6424.91

Tevogen, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Employees18
IPOJan 05, 2022
Beta0.24
ATR, 14d0.47
Rel volume0.38
Insider own0.00%
Inst own1.62%

Snapshot

6 groups

Valuation

Index-
Market Cap39.07M
Enterprise Value56.23M
Income-22.14M
Sales0.00M
Book/sh-4.16
Cash/sh0.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees18
IPOJan 05, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C36.18
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.33
Current Ratio0.33
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-5.83
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -305.12%
Sales past 3/5Y- -
EPS Y/Y TTM36.06%
Sales Y/Y TTM-
EPS Q/Q0.36%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.50.66% -

Ownership

Insider Own0.00%
Insider Trans-
Inst Own1.62%
Inst Trans-71.70%
ROA-480.45%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-3.37%
SMA50-11.46%
SMA200-22.97%
Trades-

Technical

Shs Outstand4.26M
Shs Float-
Short Float-
Short Ratio6.65
Short Interest0.05M
52W High24.91 -75.91%
52W Low3.64 65.00%
Volatility5.43% 7.20%
ATR (14)0.47
RSI (14)45.68
Beta0.24
Rel Volume0.38
Avg Volume8.25K
Volume3,141

Performance

Perf Week4.90%
Perf Month-15.61%
Perf Quarter-8.68%
Perf Half Y-11.37%
Perf YTD-63.76%
Perf Year-74.47%
Perf 3Y-98.90%
Perf 5Y-
Perf 10Y-
Recom3.00
Target Price100.00
Prev Close5.72
Price6.00
Change %4.90%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Mar 04, 2026DowngradeDD. Boral CapitalBuy → Hold
Mar 04, 2025InitiatedDD. Boral CapitalBuy$10+66.7%

Peers

Mkt cap
TickerCompanyMkt cap
ATRAAtara Biotherapeutics Inc82.61M
TCRXTscan Therapeutics Inc12.58M
MRKRMarker Therapeutics Inc15.84M
TILInstil Bio Inc42.80M
ALLOAllogene Therapeutics Inc311.85M
ESLAEstrella Immunopharma Inc34.53M
LYELLyell Immunopharma Inc414.51M
IPSCCentury Therapeutics Inc315.07M
NKTXNkarta Inc106.12M
GTBPGT Biopharma Inc8.14M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Flomenberg NealSee RemarksMar 11 '26Sale7.264523,28277,441Mar 17 04:29 PM
Flomenberg NealSee RemarksMar 13 '26Sale6.405013,20676,940Mar 17 04:29 PM
Flomenberg NealSee RemarksMar 10 '26Sale7.751914777,893Mar 17 04:29 PM
Desai KirtiOfficerFeb 06 '26Proposed Sale0.31330,000103,224Feb 06 03:09 PM
Desai KirtiOfficerDec 30 '25Proposed Sale0.4015,5006,149Dec 30 10:12 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement (GlobeNewswire)
  • UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC (GlobeNewswire) +8.78%
  • Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC (GlobeNewswire)
  • Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements (GlobeNewswire)
  • Tevogen Bio Holdings Inc. Becomes Tevogen Inc. (GlobeNewswire) +6.26%
  • Tevogen Bio Announces 2026 Annual Meeting of Stockholders (GlobeNewswire)
  • Tevogen Announces Formation of a Healthcare Services Initiative (GlobeNewswire) -7.65%
  • Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue (GlobeNewswire) +11.82%
  • Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization (GlobeNewswire) +10.35%
  • Letter to Shareholders from CEO Dr. Ryan Saadi (GlobeNewswire) +11.70%
  • Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close (GlobeNewswire)
  • Tevogen.AI Nears Completion of PredicTcell Training; Initiates Commercial Readiness and Debuts Internal Application Portal (GlobeNewswire) -7.28%
  • Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth (GlobeNewswire) -8.11%
  • Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q42026-02-25-1.500-1.500-1.1980.00-1
2025Q32025-11-14-1.500-3.040-1.5000.000.001
2025Q22025-08-14-1.530-2.500-1.5310.000.001
2025Q12025-05-28-3.500-2.435-3.2540.000.001
2024Q42025-04-30-1.700-1.700-2.5990.000.001
2026Q1---2.000-1.612--1
2026Q2---2.000-1.525--1
2026Q3---2.000---1
2026Q4---2.000---1
2027Q1---3.385---1
2027Q2---3.255---1
2027Q3---3.275---1
2027Q4---3.090---1
2028Q1---4.680---1
2028Q2---4.495---1
2028Q3---4.525---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-2.500-19.500-19.5000.000.00
2025FY-7.500-7.500-8.0810.000.00
2026FY--7.500--0.00
2027FY--9.500--0.00
2028FY--13.000---
2029FY-15.500--307.42
2030FY-55.000--724.49

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q1S2025-11-141000.000.000.00
2026Q1S2025-08-141000.000.000.00
2026Q1S2025-05-281000.000.000.00
2026Q1S2025-04-301000.000.000.00
2026Q1S2025-04-251000.000.000.00
2026Q1S2025-04-241000.000.000.00
2026Q1S2025-04-231000.000.000.00
2026Q1S2025-04-221000.000.000.00
2026Q1S2025-04-211000.000.000.00
2026Q1S2025-04-201000.000.000.00
2026Q1S2025-04-191000.000.000.00
2026Q1S2025-04-181000.000.000.00
2026Q1R2026-03-03110-2.00-2.00-2.00
2026Q1R2026-03-02110-2.64-2.64-2.64

Estimate history

EPS, annual-0.034.599-122.168-3.503-8.081-5.8309
Period20212022202320242025TTM
EPS, quarterly-1.971-1.737-2.599-3.254-1.531-1.496-1.198-1.612-1.525
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.9590.9592.43.564.0214.255
Period20212022202320242025MRQ
Shares, quarterly3.3773.4153.563.6783.8743.9484.0214.1694.255
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.230.510.400.380.000.00
Gross Profit-0.23-0.51-0.40-0.380.000.00
Selling, General and Administrative Excl. Other21.1725.6353.168.460.950.18
Research and Development11.6311.1131.034.40--
Other Operating Expense0.000.000.000.000.000.00
Operating Income-21.40-26.14-53.56-8.84-0.95-0.18
Interest Expense0.300.200.181.210.000.00
Unusual Expense-0.09-0.06-40.0250.43-0.41-0.14
Net Income Before Taxes-21.61-26.28-13.73-60.484.41-0.03
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-21.61-26.28-10.11-60.484.41-0.03
Net Income From Continuing Operations-21.61-26.28-10.11-60.484.41-0.03
Net Income-22.14-26.83-10.27-60.484.41-0.03
EPS (Recurring)-5.80-8.09-13.05-50.864.30-0.13
EPS (Basic, Before Extraordinaries)-5.83-8.08-3.50-122.174.60-0.03
EPS (Diluted)-5.83-8.08-3.50-122.174.60-0.03
EBITDA-21.17-25.63-53.16-8.46-0.95-0.18
Non-Operating Income (Expense)0.000.000.000.004.950.02
Other After Tax Adjustments0.000.003.610.000.000.00
Stock Option Compensation Expense11.8316.2240.76---
Price To Earnings Ratio---161.80278.66278.66
Shares Outstanding4.264.023.562.400.960.96
Market Capitalization39.0739.0767.36176.04495.15495.15

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.060.090.030.290.110.100.10
Gross Profit-0.06-0.06-0.09-0.03-0.29-0.11-0.10-0.10
Selling, General and Administrative Excl. Other5.605.344.525.705.1510.259.265.98
Research and Development3.283.132.113.112.703.202.843.26
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.66-5.40-4.61-5.73-5.44-10.36-9.36-6.09
Interest Expense0.100.070.070.060.040.020.020.01
Unusual Expense0.00-0.03-0.00-0.060.02-0.010.07-0.21
Net Income Before Taxes-5.76-5.45-4.68-5.73-5.50-10.37-9.44-5.88
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.76-5.45-4.68-5.73-5.50-10.37-9.25-5.91
Net Income From Continuing Operations-5.76-5.45-4.68-5.73-5.50-10.37-9.25-5.91
Net Income-5.84-5.62-4.82-5.86-5.64-10.50-9.25-5.91
EPS (Recurring)-1.52-1.62-1.20-1.51-1.53-3.26-2.59-1.78
EPS (Basic, Before Extraordinaries)-1.52-1.61-1.20-1.50-1.53-3.25-2.60-1.74
EPS (Diluted)-1.52-1.61-1.20-1.50-1.53-3.25-2.60-1.74
EBITDA-5.60-5.34-4.52-5.70-5.15-10.25-9.26-5.98
Non-Operating Income (Expense)0.000.000.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.19-0.03
Stock Option Compensation Expense3.292.852.453.243.247.296.963.33
Shares Outstanding4.264.174.023.953.873.683.563.42
Market Capitalization39.0718.3066.56155.01242.12198.6067.3667.36

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments0.551.281.050.130.34
Short Term Receivables0.160.160.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets0.830.920.670.150.45
Total Current Assets1.542.361.720.270.79
Net Property, Plant & Equipment1.590.520.930.000.00
Total Investments and Advances0.000.000.00356.86351.92
Intangible Assets--0.000.000.00
Other Assets1.250.582.850.000.15
Total Assets4.383.465.51357.14352.85
Short Term Debt Incl. Current Port. of LT Debt1.981.8880.960.000.00
Accounts Payable0.000.000.000.000.00
Other Current Liabilities5.097.164.510.350.06
Total Current Liabilities7.079.0485.480.350.06
Long Term Debt5.521.0114.450.000.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.030.090.0014.7115.12
Total Liabilities12.6210.1499.9315.0615.18
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value8.808.800.000.000.00
Common Equity-17.03-15.47-94.43342.08337.67
Total Shareholders Equity-8.23-6.67-94.43342.08337.67
Accumulated Minority Interest0.000.000.000.000.00
Total Equity-8.23-6.67-94.43342.08337.67
Total Liabilities & Stockholders Equity4.383.465.51357.14352.85
Book Value Per Share-4.24-4.35-39.35356.83352.23
Tangible Book Value Per Share-4.24-4.35-39.35356.83352.23
Full-Time Employees18181733
Price to Book Ratio-1.44-96.8117.881.461.46
Return on Assets-669.89-98.68-33.351.24-
Return on Equity---48.841.30-
Return on Invested Capital---1.29-0.01
Quick Ratio0.220.260.020.7813.33
Current Ratio0.220.260.020.7813.33

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-21.61-26.28-13.73-60.484.41-0.03
Depreciation0.230.510.400.38--
Other Funds (Non Cash)11.7416.161.3351.63-5.36-0.15
Funds from Operations-9.64-9.60-11.99-8.46-0.95-0.18
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.93-2.72-0.010.290.74-0.53
Cash from Operating Activities-11.57-12.33-12.00-8.17-0.22-0.71
Capital Expenditures-0.06-0.060.00-0.130.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00-351.90
Purchase of Investments0.000.000.000.000.00-351.90
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.06-0.060.00-0.130.00-351.90
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock9.034.768.00-0.130.00352.96
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.034.768.00-0.130.00352.96
Proceedsfrom Stock Options6.064.768.00-0.130.00352.96
Issuance or Reduction of Debt, Net2.003.401.004.000.000.00
Change in Long Term Debt2.003.401.004.000.000.00
Issuance of Long Term Debt2.003.401.004.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow1.003.503.230.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities12.0311.6612.233.870.00352.96
Net Change in Cash0.40-0.730.23-4.43-0.220.34
Free Cash Flow-11.63-12.39-12.00-8.30-0.22-0.71
Preferred Dividends (Cash Flow)---0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments1.080.690.551.040.691.97
Short Term Receivables0.160.160.160.160.160.16
Inventories0.000.000.000.000.000.00
Other Current Assets0.771.290.830.931.220.94
Total Current Assets2.012.141.542.122.063.08
Net Property, Plant & Equipment1.471.531.591.621.640.42
Total Investments and Advances0.000.000.000.000.000.00
Other Assets1.241.251.250.760.570.58
Total Assets4.734.924.384.494.274.07
Short Term Debt Incl. Current Port. of LT Debt1.981.981.981.981.981.82
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities4.175.295.094.766.106.90
Total Current Liabilities6.157.277.076.748.088.72
Long Term Debt7.467.495.525.555.583.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.030.030.090.07
Total Liabilities13.6214.7612.6212.3213.7511.79
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value8.808.808.808.808.808.80
Common Equity-17.69-18.64-17.03-16.62-18.28-16.52
Total Shareholders Equity-8.89-9.84-8.23-7.82-9.48-7.72
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-8.89-9.84-8.23-7.82-9.48-7.72
Total Liabilities & Stockholders Equity4.734.924.384.494.274.07
Book Value Per Share-4.16-4.47-4.24-4.21-4.72-4.49
Tangible Book Value Per Share-4.16-4.47-4.24-4.21-4.72-4.49
Full-Time Employees--18---
Price to Book Ratio-1.44-1.07-3.91-9.32-13.24-12.02
Return on Assets-480.45-474.85-669.89-702.43-818.81-849.23
Quick Ratio0.330.290.220.310.250.35
Current Ratio0.330.290.220.310.250.35

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.76-5.45-4.68-5.73-5.50-10.37
Depreciation0.060.060.090.030.290.11
Other Funds (Non Cash)3.292.822.443.183.247.30
Funds from Operations-2.41-2.56-2.15-2.52-1.98-2.96
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.59-0.17-0.03-1.13-1.21-0.35
Cash from Operating Activities-3.01-2.73-2.18-3.65-3.19-3.31
Capital Expenditures0.000.00-0.060.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.060.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock3.400.871.763.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.400.871.763.000.000.00
Proceedsfrom Stock Options0.430.871.763.000.000.00
Issuance or Reduction of Debt, Net0.002.000.000.001.402.00
Change in Long Term Debt0.002.000.000.001.402.00
Issuance of Long Term Debt0.002.000.000.001.402.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.001.000.502.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.402.871.764.001.904.00
Net Change in Cash0.390.14-0.480.35-1.290.69
Free Cash Flow-3.01-2.73-2.25-3.65-3.19-3.31

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.1M-8.58K
2026-10-15-0.1M-9.08K
2026-09-305.85%0.1M1.0M10.95K
2026-09-156.14%0.1M1.0M14.27K
2026-08-312.81%0.1M2.1M17.39K
2026-08-142.74%0.1M2.1M23.51K
2026-07-313.48%0.1M2.0M26.88K
2026-07-155.90%0.1M1.1M28.36K
2026-06-306.05%0.1M1.1M29.55K
2026-06-157.63%0.1M1.1M31.96K
2026-05-2910.37%0.1M1.1M37.49K
2026-05-1511.38%0.1M1.1M32.67K
2026-04-3011.14%0.1M1.0M29.63K
2026-04-159.50%0.1M1.0M28.34K
2026-03-3112.71%0.1M0.9M27.15K
2026-03-139.76%0.1M0.9M21.36K
2026-02-276.64%0.1M0.9M18.31K
2026-02-136.87%0.1M0.9M17.97K
2026-01-304.48%0.1M1.1M18.52K
2026-01-154.78%0.1M1.1M17.26K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04SCHEDULE 13D/ASEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-048-KCurrent report2026-11-02SEC
2026-11-038-KCurrent report2026-10-27SEC
2026-09-308-KCurrent report2026-09-29SEC
2026-09-168-KCurrent report2026-09-14SEC
2026-09-16SCHEDULE 13D/ASEC
2026-09-16SCHEDULE 13D/ASEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-108-KCurrent report2026-09-09SEC
2026-08-268-KCurrent report2026-08-24SEC
2026-08-24S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-03SEC
2026-07-308-KCurrent report2026-07-29SEC
2026-07-23PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-23SEC
2026-07-14SCHEDULE 13D/ASEC
2026-07-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03006.64K3
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC0.57%
MORGAN STANLEY0.45%
AQR CAPITAL MANAGEMENT LLC0.41%
GOLDMAN SACHS GROUP INC0.34%
JANE STREET GROUP, LLC0.26%
GEODE CAPITAL MANAGEMENT, LLC0.18%
Russell Investments Group, Ltd.0.06%
Tower Research Capital LLC0.04%
VANGUARD FIDUCIARY TRUST CO0.02%
GAMMA Investing LLC0.02%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.36%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.17%
Goldman Sachs Absolute Return Tracker Fund0.15%
Fidelity Small Cap Index Fund0.13%
VANGUARD RUSSELL 2000 INDEX FUND0.10%
Fidelity Nasdaq Composite Index Fund0.06%
VANGUARD EXTENDED MARKET INDEX FUND0.04%
Schwab Small-Cap Index Fund0.04%
Fidelity Extended Market Index Fund0.02%
Global Multi-Strategy Fund0.01%

OakChart. TVGN. Cached 15 minutes.